Platt Investment Counsel LLC Purchases New Position in Bristol Myers Squibb Company $BMY

Platt Investment Counsel LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 8,525 shares of the biopharmaceutical company’s stock, valued at approximately $491,000. Bristol Myers Squibb comprises 0.3% of Platt Investment Counsel LLC’s investment portfolio, making the stock its 10th largest holding.

Several other hedge funds have also bought and sold shares of the stock. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the second quarter worth $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Bayban acquired a new stake in Bristol Myers Squibb during the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on BMY. Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Guggenheim restated a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Wednesday. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Bristol Myers Squibb Trading Up 0.7%

Shares of BMY stock opened at $64.63 on Friday. The stock’s fifty day moving average is $58.71 and its two-hundred day moving average is $58.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $132.02 billion, a P/E ratio of 14.24, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.96 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.